Alpha 2.0
Login Register
» Authors » G Hoeffken

G Hoeffken

Explore the profile of G Hoeffken including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 449
Followers 0
Related Specialties
Pulmonary Medicine
Oncology
Pharmacology
Top 10 Co-Authors
M Halank
H J Seyfarth
M M Hoeper
C Marx
R Ewert
C Rubens
T Welte
M Kolditz
E Thiel
R Wensel
Published In
Eur Respir J
Cancer Detect Prev
Antimicrob Agents Chemother
Thorax
Respir Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Phase-I tolerability study of 5-methyltetrahydrofolate in combination with a 4-hour infusion of 5-Fluorouracil in cancer-patients
Korfel A, Kreuser E, Hoeffken G, Baumgart J, Sass G, Thiel E, et al.
Int J Oncol . 2011 May; 7(1):65-8. PMID: 21552807
5-methyltetrahydrofolate (MTHF) is a main serum metabolite of 5-formyltetrahydrofolate (folinic acid, FA), a standard agent for potentiation of the cytotoxic activity of 5-fluorouracil (5-FU). The clinical application of MTHF instead...
2.
New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality
Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, et al.
Thorax . 2009 May; 64(12):1062-9. PMID: 19454409
Background: The database of the German programme for quality in healthcare including data of every hospitalised patient with community-acquired pneumonia (CAP) during a 2-year period (n = 388 406 patients...
3.
L-arginine plasma levels and severity of idiopathic pulmonary arterial hypertension
Beyer J, Kolditz M, Ewert R, Rubens C, Opitz C, Schellong S, et al.
Vasa . 2008 Jun; 37(1):61-7. PMID: 18512543
Background: Idiopathic pulmonary arterial hypertension (iPAH) is a rare disease of unknown aetiology characterized by a poor prognosis. Impairment of nitric oxide (NO) synthesis or NO-induced vasorelaxation has been suspected...
4.
Experience with inhaled iloprost and bosentan in portopulmonary hypertension
Hoeper M, Seyfarth H, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz M, et al.
Eur Respir J . 2007 Jul; 30(6):1096-102. PMID: 17652314
Novel treatments, such as prostanoids or endothelin receptor antagonists, have been introduced for various forms of pulmonary arterial hypertension, but the long-term effects of these treatments on portopulmonary hypertension (PPHT)...
5.
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
Hoeper M, Leuchte H, Halank M, Wilkens H, Meyer F, Seyfarth H, et al.
Eur Respir J . 2006 Oct; 28(4):691-4. PMID: 17012628
Addition of inhaled iloprost to bosentan may have beneficial effects in patients with idiopathic pulmonary arterial hypertension (IPAH). A multicentre, open, randomised, controlled trial was performed to assess the safety...
6.
[Portopulmonary hypertension]
Halank M, Miehlke S, Kolditz M, Hoeffken G
Z Gastroenterol . 2005 Jul; 43(7):677-85. PMID: 16001350
Patients with portal hypertension may develop pulmonary complications such as hepatopulmonary syndrome (HPS) or portopulmonary hypertension (PPHT). PPHT is defined as elevated pulmonary pressure, elevated pulmonary vascular resistance, a normal...
7.
Bosentan therapy for portopulmonary hypertension
Hoeper M, Halank M, Marx C, Hoeffken G, Seyfarth H, Schauer J, et al.
Eur Respir J . 2005 Mar; 25(3):502-8. PMID: 15738295
The dual endothelin receptor antagonist bosentan has been approved in several countries for pulmonary arterial hypertension, and patients with portopulmonary hypertension (PPHTN) have not specifically been excluded. However, no data...
8.
Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens
Hoeffken G, Talan D, Larsen L, Peloquin S, Choudhri S, Haverstock D, et al.
Eur J Clin Microbiol Infect Dis . 2004 Dec; 23(10):772-5. PMID: 15605184
In two prospective, randomized studies intravenous (IV)/oral (PO) moxifloxacin (400 mg q.i.d.) was compared to IV/PO antimicrobial comparator agents for the treatment of hospitalized patients with community-acquired pneumonia. Reported here...
9.
Long term survival in primary pulmonary hypertension
Halank M, Marx C, Hoeffken G
Heart . 2004 Jun; 90(7):e40. PMID: 15201266
The mean survival of patients with severe primary pulmonary hypertension (PPH) is < 3 years without appropriate treatment. There are no long term reports on the spontaneous course of mild...
10.
Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment
Finch R, Schurmann D, Collins O, KUBIN R, McGivern J, Bobbaers H, et al.
Antimicrob Agents Chemother . 2002 May; 46(6):1746-54. PMID: 12019085
The objective of the present trial was to compare the efficacy, safety, and tolerability of moxifloxacin (400 mg) given intravenously (i.v.) once daily followed by oral moxifloxacin (400 mg) for...